Fundraising Fox
Eyconis
Redwood City, US · Founded 2023 · Delaware corporation · 49 employees on LinkedIn · 5 known investors
Find your way into Eyconis
Sign up to see every warm intro you have to Eyconis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eyconis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.
Founders & leadership
Board
Investors · 5
How we know: Frazier Life Sciences's portfolio page · the company's own site · funding news · Not right? Tell us
How we know: the company's own site · funding news · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$85.3M disclosed across 2 rounds · 2024–2025
▶$25MraisedOct 2025 · 7 investors · OtherRule 506(b)
- Conrad WangDirector
- Yvonne YamanakaDirector
- Emmett CunninghamExecutive Officer, Director
- Mark BachledaExecutive Officer, Director
- Robert VittiExecutive Officer
- Dan EstesDirector
- Anna ChenDirector
- Oliver StauchExecutive Officer
- Jan Moller MikkelsenDirector
- Offering amount
- $89.8M
- Amount sold
- $25M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$60.3MraisedFeb 2024 · 7 investors · OtherRule 506(b)
- Daniel EstesExecutive Officer, Director, Promoter
- Oliver Boris StauchExecutive Officer
- Emmett CunninghamExecutive Officer, Director, Promoter
- Jan Moller MikkelsenDirector
- Gordon EmpeyExecutive Officer, Promoter
- Conrad WangDirector
- Yvonne YamanakaDirector
- Anna ChenExecutive Officer, Director, Promoter
- Offering amount
- $150M
- Amount sold
- $60.3M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Eyconis.
In the news
Frequently asked questions
- What does Eyconis do?
- Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.
- Who are Eyconis's investors?
- Eyconis's investors include Frazier Life Sciences, HealthQuest Capital, venBio Partners, RA Capital, venBio Global Strategic.
- How much funding has Eyconis raised?
- Eyconis has disclosed $85.3M raised across 2 rounds.
- Where is Eyconis headquartered?
- Eyconis is headquartered in Redwood City, US.